Nonetheless, ADCs with camptothecin derivatives, such as trastuzumab deruxtecan (Enhertu) for HER2-positive cancers and sacituzumab govitecan (Trodelvy) for Trop-2-expressing cancers, have demonstrated significant efficacy, underscoring the clinical potential of camptothecin-based payloads in oncology [42, 43]. This evidence concerns the gene TACSTD2 and cancer.